The rise of Viagra and its impact on the drug landscape presents a complex question for investors. While the first sales data were impressive, the intellectual property has lapsed, leading to a flood of off-brand alternatives that are eroding earnings. Furthermore, the market is facing issues related to demographic trends and evolving healthcare po